Telix Pharmaceuticals Ltd
ASX:TLX

Watchlist Manager
Telix Pharmaceuticals Ltd Logo
Telix Pharmaceuticals Ltd
ASX:TLX
Watchlist
Price: 24.62 AUD -1.01% Market Closed
Market Cap: 8.2B AUD
Have any thoughts about
Telix Pharmaceuticals Ltd?
Write Note

Telix Pharmaceuticals Ltd
Cost of Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Telix Pharmaceuticals Ltd
Cost of Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cost of Revenue CAGR 3Y CAGR 5Y CAGR 10Y
Telix Pharmaceuticals Ltd
ASX:TLX
Cost of Revenue
-AU$188.2m
CAGR 3-Years
-353%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Immutep Ltd
ASX:IMM
Cost of Revenue
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Mesoblast Ltd
ASX:MSB
Cost of Revenue
-$15.7m
CAGR 3-Years
22%
CAGR 5-Years
0%
CAGR 10-Years
N/A
CSL Ltd
ASX:CSL
Cost of Revenue
-$7.1B
CAGR 3-Years
-17%
CAGR 5-Years
-14%
CAGR 10-Years
-11%
Clinuvel Pharmaceuticals Ltd
ASX:CUV
Cost of Revenue
AU$1.1m
CAGR 3-Years
-16%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
PYC Therapeutics Ltd
ASX:PYC
Cost of Revenue
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Telix Pharmaceuticals Ltd
Glance View

Market Cap
8.2B AUD
Industry
Biotechnology
Economic Moat
Wide

Telix Pharmaceuticals Ltd. is an innovative biopharmaceutical company that has carved a niche for itself in the realm of targeted radiation therapy and imaging, primarily focusing on cancer treatment. Established with the vision of transforming the landscape of oncology, Telix develops molecularly-targeted radiation (MTR) products aimed at diagnosing and treating a range of significant unmet medical needs. The company's lead product, Illuccix, gained significant attention after securing regulatory approvals for use in imaging prostate cancer. Through strategic alliances with academic and research institutions, as well as commercial entities, Telix harnesses the power of radioisotopes to create compounds that bind to specific cancer cells, allowing for both precise imaging and treatment of malignancies. The business model of Telix hinges on a blend of research and development, regulatory acumen, and strategic commercialization. By advancing a pipeline of diagnostic and therapeutic radiopharmaceuticals, Telix aims to address the full cycle of cancer care—from early detection to personalized treatment. Revenue is primarily generated through the sale of its approved products, alongside potential milestone payments and royalties from partnerships. The commercial success of Illuccix and other pipeline candidates underscores the company's ability to effectively translate scientific research into marketable therapies, positioning Telix as a formidable player in the competitive arena of cancer diagnosis and treatment. By continuing to expand its portfolio and push the boundaries of nuclear medicine, Telix seeks to deliver life-changing therapies while driving sustainable growth.

TLX Intrinsic Value
16.51 AUD
Overvaluation 33%
Intrinsic Value
Price

See Also

What is Telix Pharmaceuticals Ltd's Cost of Revenue?
Cost of Revenue
-188.2m AUD

Based on the financial report for Dec 31, 2023, Telix Pharmaceuticals Ltd's Cost of Revenue amounts to -188.2m AUD.

What is Telix Pharmaceuticals Ltd's Cost of Revenue growth rate?
Cost of Revenue CAGR 3Y
-353%

Over the last year, the Cost of Revenue growth was -189%. The average annual Cost of Revenue growth rates for Telix Pharmaceuticals Ltd have been -353% over the past three years .

Back to Top